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LLL01
ASIAN CONTRIBUTION IN LIVING
DONOR LIVER TRANSPLANTATION
Masatoshi Makuuchi
Japanese Red Cross Medical Center, Japan
With the efforts of hepatic surgeons around the world,
living donor liver transplantation has become a realistic
choice for patients with serious liver diseases. In my
lecture, I am going to talk about the Asian contribu-
tion in expansion of Milan Criteria, vein reconstruction
using artificial vein, methods to overcome small-for-size
graft, dual left lobe graft, ABO-incompatible transplan-
tation, inflow modulation, PVP and splenectomy, and
new drug therapies for LDLT.
LLL02
HAZARD AND NECESSITY: HOW
LIVER SURGERY ENTERED INTO
LIVER TRANSPLANTATION
Henri Bismuth
Hopital paul brousse hepatobiliary, France
The Nobel Price Jacques Monod said in his book
“Natural Philosophy of Modern Biology” that evolu-
tion of the living obeys to the rules of both Hazard
and Necessity. It could be true in Medicine and how
liver surgery entered into the field of liver transplanta-
tion is an example. Scientific discovery may obey to the
same mecanism.
LLL03
SURGICAL CHALLENGES TO BILIARY
CANCERS
Yuji Nimura
Aichi Cancer Center, Japan
Surgical resection is an only curative treatment of
choice for biliary cancers, and surgical challenges to
difficult biliary cancers - gallbladder cancer and proxi-
mal cholangiocarcinoma - have been offered since the
late 19th century. Successful reports of gallbladder bed
resection with or without bile duct resection was pub-
lished in 1897, and the resected patients survived for 2
- 3 month. Also several surgical challenges with biliary
drainage were applied for proximal cholangiocarcinoma
since the late 19th century. However, successful resec-
tion of middle bile duct cancer was delayed and
reported in 1903 and tumorectomy for papillary cancer
at the hepatic duct in 1935. The former patient sur-
vived for 27 months and the latter 45 months. The
details of radical resection of hilar cholangiocarcinoma
and gallbladder cancer were reported incidentally in the
same year, 1954 by Brown (transthoracoabdominal bile
duct resection) and Glenn (radical cholecystectomy).
The first successful major hepatectomy (right lobec-
tomy = right trisectionectomy) for gallbladder cancer
was reported by Pack in 1955. Aggressive hepatectomy
with or without pancreatoduodenectomy for locally
advanced gallbladder cancer has mainly been carried
out in Japan since 1970s. Also several types for hepa-
tectomy - gallbladder bed resection, S4a+5 resection,
central bisectionectomy, extended right hepatectomy
and right trisectionectomy - were planned according to
the local extension of the tumor since 1990s. However,
we have not reached to a consensus on the surgical
indication of the above hepatectomy for locally
advanced gallbladder cancer. On the other hand, sev-
eral options have been developed and actually used for
hilar cholangiocarcinoma since the first successful hepa-
tobiliary resection in 1962, combined liver and portal
vein resection in 1965 and liver and hepatic artery
resection and reconstruction in1983. Liver transplanta-
tion was reported since 1976 with varying degree of
success. Since 1990s, major hepatectomy has been
applied in the leading hospitals all over the world after
developing perioperative management techniques for
high risk patients with difficult hilar cholangiocarcino-
ma. Preoperative biliary drainage followed by portal
vein embolization decreased morbidity and mortality
after aggressive hepatobiliary resection, and improved
long-term survival for hepatectomized patients under-
going concomitant hepatic artery and portal vein resec-
tion with or without pancreatoduodenectomy has been
reported. RCT should be planned and actually be car-
ried out to reveal the value of extended lymphadenecto-
my in hepatobiliary resection for not only gallbladder
cancer but also for hilar cholangiocarcinoma.
PL01
GREAT SAPHENOUS VEIN IS THE




Asan Medical Center, Ulsan University, Korea
Hepato-Biliary-Pancreas (HBP) malignancies often
invade major hepatic vein (HV) or portal vein (PV).
Curative resection of these cancers can be achieved by
complete removal of the infiltrated vein and subsequent
reconstruction with an interposition or patch vascular
graft for the rescue of patients. Autologous external
iliac vein (EIV), internal jugular vein (IJV), Left renal
vein (LRV) and superficial femoral vein (SFV) have
been used as vein grafts; these vein grafts can ensure an
ample diameter and length for reconstruction of such
intrinsic veins. However, the sacrifice of EIV and SFV,
IJV and LRV is sometimes associated with postopera-
tive edema of lower leg and face or impairment of renal
function in poor-risk patients, and requires extensive
dissection area. Historically, great saphenous vein
(GSV) has been used as coronary conduits for ischemic
heart disease because its wall is healthy enough to with-
stand a high arterial pressure. GSV is sacrificed with
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minimal disadvantages to patients, but its luminal
diameter is not suitable to size-match for interposing a
major HV or PV. The small luminal diameter of GSV
(3-5 mm) cannot deliver a sufficient blood flow as a
substitute for major HV or PV. To resolve this
dilemma, the method of “customized saphenous vein
tube graft” was developed by a few experienced HBP
surgery centers. The harvested autogenous GSV is split-
ted longitudinally after hydrostatic dilatation, then
divided into 3 or 4 segments and aligned side-to-side / or
spirally sutured continuously over the 2cm-sized syringe
to construct a vessel tube for replacement of the future
resecting HV or PV. Besides HBP cancer surgery, GSV is
an indispensible material to reconstruct the stenosed and
damaged PV by portal vein thrombosis and HV outflow
in living-donor liver transplantation (LDLT). In LDLT
as well as whole-size deceased-donor liver transplanta-
tion, presence of PVT in recipient is frequently regarded
as a relative or absolute contraindication of transplant,
because of poor outcomes and high mortality rate in
addition to technical difficulties. Homologous cryopre-
served vein or artificial PTFE vascular graft are not good
substitutes of PV, especially in the presence of portal
hypertension for LDLT because anastomosis suture line
is easily torn by the damaged weak intima of recipient
PV and rethrombosis rate is high by aneurismal dilata-
tion of cryopreserved vein or infection of the artificial
graft . GSV can endure portal hypertensive pressure as it
did endure arterial pressure for coronary bypass surgery.
Remodeled GSV with its enlarged diameter for the sub-
stitute of PV or HV in HBP cancer surgery and LDLT is
the great gift from God to HBP and liver transplantation
surgeons, especially when fresh cadaveric vascular grafts
are not available. In present study, our surgical experi-
ences of “the customized GSV vascular condult ” in
HBP Surgery and the challenging LDLT are reviewed.
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